Anheuser-Busch Expands Its 9/11 Partnership - But the Real Story Is What Its Revenue Numbers Are Hiding

Anheuser-Busch announced on August 5, 2026, that it is expanding its longstanding partnership with the Tunnel to Towers Foundation for the 25th anniversary of September 11th. The foundation provides mortgage-free homes to families of fallen first responders. The Steel Across America tour, which carries a World Trade Center steel beam across multiple cities, now has AB InBev's corporate backing woven deeper into its commemoration.

It's a worthy story. But the numbers behind the brand tell a different one - and for an income-focused investor, those numbers are the only ones that decide whether BUD stock belongs in your portfolio.

The pricing power test

Here is the metric that matters more than any press release: AB InBev reported $31.9 billion in revenue for the first half of 2026, up 11.5% year over year. Volume - the actual number of units sold - grew just 0.3%. Nearly all of that top-line growth came from higher prices and a shift toward its premium brands.

If you don't know what to do with that, let me translate it. When a company can grow revenue by more than 11% without selling more product, it has pricing power. Consumers are paying more per six-pack and buying the premium labels - Corona, Stella Artois, Budweiser, Michelob Ultra - instead of trading down. In an inflationary environment, that is the single most important filter I apply to any dividend stock. If a company can't raise prices without losing customers, it can't grow its dividend through inflation. BUD passes that test decisively.

The dividend: conservative payout, enormous runway

BUD's trailing dividend yield sits at roughly 1.2%. That is not a yield that grabs attention. If you're fishing for current income, this isn't your ticker. But yield is a lagging snapshot of what happened yesterday. The payout ratio is the leading indicator of where the dividend is going.

AB InBev's payout ratio - the percentage of earnings paid out as dividends - is 21.1%. That is extraordinarily conservative for a mature beverage company. Most dividend growers in the consumer staples space run payout ratios between 50% and 70%. Constellation Brands (STZ), its closest US peer, pays out roughly 39% of earnings. BUD is paying out about half of what its rival does.

A 21% payout ratio means management has massive room to accelerate dividend growth without touching balance-sheet stability. The company has now grown its dividend for 13 consecutive years. Free cash flow over the trailing twelve months stands at $13.8 billion. Even if you assume management never raises the payout ratio, that free cash flow generates enough cushion to fund double-digit dividend increases without stress.

The balance sheet: the one scar on the model

Here is the real risk. AB InBev carries $117 billion in total debt. Net debt - total debt minus cash - is $64 billion. The debt-to-equity ratio is 71.5%. This is not a lean balance sheet.

But the debt story has two sides. Operating cash flow for the trailing twelve months is $17.4 billion. Free cash flow after capital expenditures is $13.8 billion, and it grew 18% year over year. At that cash generation rate, the company can service its debt load and still direct meaningful capital back to shareholders. The heavy debt is a legacy of AB InBev's aggressive M&A history - this company has grown through acquisition, and the bill came due in the form of leverage. What matters going forward is whether cash flow growth stays ahead of debt service, and the current trajectory says it is.

Valuation after a 33% run

BUD is trading near $85, up roughly 33% year-to-date and sitting close to its 52-week high. The stock trades at about 18 times trailing earnings and 22 times forward earnings. EV/EBITDA - enterprise value divided by earnings before interest, taxes, depreciation, and amortization, a measure that captures the full value of the business relative to its cash-generating capacity - is 8.2x. The PEG ratio (price-to-earnings divided by earnings growth rate) is 0.55, which would normally signal a stock trading well below its growth rate.

Here is the framing question: at 33% YTD gains, has the market already done the work for you? The trailing PE of 18x is not cheap for a consumer staples company, but it's not outrageous either. The forward PE of 22x starts to feel like it's assuming continued premium pricing and steady execution. If inflation persists at a level above the old 2% target - which I believe is likely given structural drivers like deglobalization, fiscal pressures, and supply-chain reshoring - companies with BUD's pricing power deserve a multiple premium. But the premium has to be justified by execution, not just the premise.

What about the competition?

Constellation Brands (STZ), the other major US beverage name that matters for income investors, offers a starker contrast. STZ yields 3.2% versus BUD's 1.2%, and it trades at a lower PE of 12.3x. If you need current income today, STZ is the obvious pick. But BUD's global scale, premium brand portfolio, and 21% payout ratio give it a compounding trajectory that STZ can't match from its higher starting yield. This is the equity yield curve in action: BUD sits on the moderate-yield, high-growth side of the spectrum. STZ sits on the higher-yield, moderate-growth side. Both are valid depending on whether you need income now or income growth over the next decade.

The compounding case

I don't think the Tunnel to Towers partnership is the headline investors should be fixing on. The headline is a company generating $32 billion in revenue, growing it at 11.5% with virtually no volume increase, paying out 21% of earnings as dividends, and generating $13.8 billion in free cash flow. That is a business that can compound its payout for years without overreaching.

The entry point is the debate. BUD at $85 is no longer the out-of-favor name it was a year ago. But the PEG of 0.55, the pricing power demonstrated in the latest results, and the enormous headroom in the payout ratio mean the compounding math still works. If you're a long-term income grower who can tolerate a modest current yield in exchange for the kind of payout durability that protects purchasing power through a full cycle, BUD remains a legitimate holding.

I don't think this stock fits the high-current-income sleeve. It belongs in the income-growth sleeve, where the job is compounding the dividend over a decade, not extracting maximum yield today. And that distinction - between income you need and income you're building - is the one that determines whether BUD makes sense for your portfolio.